Table 2 Differences in medical prevention with OAC, PAI, or statin at admission based on the final etiological stroke diagnosis (cardioembolic, macroangiopathic, cryptogenic, or other) and positive history of previous ischemic stroke. Intergroup differences were assessed using a chi-square test, with a significance level of p < 0.05 marked in bold. Abbreviations: PAI – platelet aggregation inhibitor, OAC – oral anticoagulation
| Â | Cardioembolic stroke | Â | Macroangiopathic stroke | Â | Cryptogenic | Â | Other strokes | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|  | No previous stroke (n = 286) | Recurrent stroke (n = 77) | Chi-square | No previous stroke (n = 211) | Recurrent stroke (n = 60) | Chi-square | No previous stroke (n = 176) | Recurrent stroke (n = 19) | Chi-square | No previous stroke (n = 33) | Recurrent stroke (n = 4) |
OAC | N = 79 27.6% | N = 36 46.8% | < 0.01 | N = 10 4.7% | N = 4 6.7% | 0.66 | N = 6 3.4% | N = 0 0,0% | 0.6 | N = 5 15.2% | N = 1 25.0% |
PAI | N = 37 12.9% | N = 9 11.7% | < 0.01 | N = 27 12.8% | N = 15 25.0% | < 0.01 | N = 18 10.2% | N = 6 31.6% | < 0.01 | N = 4 12.1% | N = 1 25.0% |
Statin alone | N = 29 10.1% | N = 21 27.3% | N = 14 6.6% | N = 10 16.7% | N = 6 3.4% | N = 0 0,0% | N = 0 0,0% | N = 1 25.0% | |||
PAI and Statin | N = 29 10.1% | N = 17 22.1% | N = 37 17.5% | N = 24 40.0% | N = 31 17.6% | N = 7 36.8% | N = 1 3.0% | N = 1 25.0% | |||
No PAI or statin | N = 191 66.8% | N = 30 39.0% | N = 133 63.0% | N = 11 18.3% | N = 121 68.8% | N = 6 31.6% | N = 28 84.8% | N = 12 25.0% | |||
OAC and PAI | N = 7 2.4% | N = 5 6.5% | 0.15 | N = 1 0.5% | N = 0 0,0% | 0.66 | N = 0 0,0% | N = 0 0,00% | - | N = 1 3.0% | N = 0 0,0% |
No OAC or PAI | N = 148 71.5% | N = 20 26.0% | < 0.01 | N = 138 65.4% | N = 17 28.3% | < 0.01 | N = 121 68.8% | N = 6 31.6% | < 0.01 | N = 24 72.7% | N = 0 0,0% |